ICG-001 can suppress BC development by targeting protein–protein interactions (PPIs) between beta-catenin and CBP, but not suppressing acetyltransferase activity (Ring et al., 2018; Sulaiman et al., 2018). This evidence concerns the gene CREBBP and breast cancer.